* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Right ventricular function in pulmonary
Survey
Document related concepts
Management of acute coronary syndrome wikipedia , lookup
Electrocardiography wikipedia , lookup
Coronary artery disease wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Cardiac surgery wikipedia , lookup
Hypertrophic cardiomyopathy wikipedia , lookup
Heart failure wikipedia , lookup
Mitral insufficiency wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Atrial septal defect wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Transcript
European Heart Journal Supplements (2007) 9 (Supplement H), H5–H9 doi:10.1093/eurheartj/sum023 Right ventricular function in pulmonary hypertension: physiological concepts Robert Naeije* and Sandrine Huez Department of Pathophysiology, Faculty of Medicine, Free University of Brussels, Erasme Campus, CP 604, 808, Lennik Road, B-1070 Brussels, Belgium KEYWORDS Pulmonary vascular resistance; Pulmonary vascular impedance; Right ventricular function; Arterial elastance; Contractility; Pulmonary hypertension The symptoms of pulmonary hypertension are explained by a decrease in cardiac output caused by an afterload-induced right ventricular (RV) failure. However, the standard haemodynamic evaluation of pulmonary hypertension, with measurements of mean pulmonary vascular pressures and cardiac output, does not capture the determinants of RV function. Right ventricular afterload can be measured either as a hydraulic load calculated from spectral analysis of pulmonary artery pressure and flow waves, or as a maximal wall tension estimated from instantaneous ventricular pressure, volume, and wall thickness measurements. The adequacy of ventricular adaptation to afterload can be assessed by a measurement of the matching of systolic function to arterial elastance. The difficulty in measuring instantaneous RV volume is overcome using a single-beat method, which derives a systolic pressure–volume relationship from instantaneous RV pressure and an integration of pulmonary arterial flow. On such a pressure–volume curve, it is easy to determine graphically end-systolic elastance (Ees, end-systolic pressure on end-systolic volume), as a load-independent measure of contractility, and arterial elastance (Ea, end-systolic pressure on stroke volume), as a measure of afterload. The optimal value of the Ees/Ea ratio, compatible with flow output at a minimal energy cost, is between 1 and 2. Patients with severe pulmonary hypertension present with a decreased elastance ratio, in spite of an adaptative increase in systolic function, which underscores that RV failure in the face of increased afterload is a relative notion. Further studies are needed to confirm that right ventriculo-arterial decoupling accounts for a decreased aerobic exercise capacity by a limitation of cardiac output adaptation to peripheral demand. Cardiac limitation to exercise capacity in pulmonary hypertension Pulmonary hypertension, as defined by an increase in mean pulmonary artery pressure (PAP) .25 mmHg at rest and/or 30 mmHg at exercise, complicates a variety of cardiac and pulmonary conditions, but may occur as a consequence of an isolated pulmonary arteriolar vasculopathy and is then called pulmonary arterial hypertension (PAH).1 The condition is either idiopathic (IPAH, formerly primary pulmonary hypertension) or occurs in * Corresponding author. Tel: þ32 2 5553322; fax: þ32 2 5554124. E-mail address: [email protected] association with a variety of diseases or circumstances, which include human immuno-deficiency syndrome, intake of fenfluramines, connective tissue disease, portal hypertension, and congenital cardiac shunts.1 Increased pulmonary vascular resistance (PVR) in PAH is associated with a progressively severe symptomatology of dyspnea, fatigue, chest pain, syncope, and right heart failure. It is remarkable that extensive vascular remodelling in PAH has actually little effect on pulmonary gas exchange. Studies using the sophisticated multiple inert gas elimination technique have shown that the distribution of ventilation/perfusion (VA/Q) relationships in these patients is close to normal,2,3 the low normal arterial PO2 being & The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: [email protected] H6 essentially to be accounted for by a low-mixed venous PO2, consequence of a low cardiac output.2,3 In some patients, there is hypoxaemia because of a right-to-left shunt through a patent foramen ovale.3 In spite of vascular obliteration, physiological dead space remains normal, at rest as well as at exercise.4 Patients with PAH hyperventilate, accounting for a typically low arterial PCO2, at rest as well as at exercise, but still do not present with a ventilatory limitation to exercise capacity.5,6 Pulmonary arterial hypertension is associated with a decrease in exercise capacity and a low cardiac output. The maximum capacity of an individual to perform aerobic work is defined by the maximum O2 consumption (VO2max), the product of maximum cardiac output by the arterio-venous O2 content difference (CaO2 2 CvO2). Because of the sigmoid shape of the oxyhaemoglobin dissociation curve, with high affinities for O2 at high and at low saturations, there is an inferior limit of CvO2 attained at the highest level of exercise. On the other hand, a VO2max is achieved on a bicycle with about half of the body’s muscles, and there is no data to suggest a skeletal muscle limitation to exercise capacity in cardiac or in pulmonary patients. It is therefore reasonable to assume that aerobic exercise capacity in PAH patients is essentially limited by cardiac output, or in case of exercise-induced hypoxaemia, by the product of cardiac output by CaO2.7 As there is a linear relationship between the running or walking speed and VO2, a 12 min run8 or a 6 min walk9 distance can be used as a surrogate of VO2max.7 Both the VO2max and the 6 min walk distance reflect the ability of the RV to increase flow output in response to peripheral O2 demand; exercise testing in PAH provides an indirect estimate of RV performance. The gold standard for the evaluation of patients with PAH is a right heart catheterization with measurements of pulmonary vascular pressures and cardiac output, and calculation of PVR.1 These measurements allow for the quantification of the severity of pulmonary vascular disease, but PVR provides only partial description of all the forces that oppose RV flow output (or afterload),10 and cardiac output is determined by loading conditions in addition to intrinsic changes in RV function.11 It is therefore understandable that standard haemodynamic measurements in patients with PAH are only loosely correlated to clinical state, functional class, exercise capacity, and prognosis, and often fail to reach significance on mean PAP.9,12–15 Measurements at exercise may provide more clinically meaningful results,16 probably because an exercise-induced increase in cardiac output may more closely reflect the functional capability of the afterloaded RV. Right ventricular failure in pulmonary hypertension Right ventricular (RV) afterload results from a dynamic interplay between resistance, elastance, and wave reflection.10 An acceptable measurement of RV afterload R. Naeije and S. Huez is given by pulmonary arterial input impedance (PVZ), which is the ratio of pulsatile PAP to pulsatile flow.10 The calculation of PVZ requires a spectral analysis of pressure and flow waves and a mathematical elaboration to derive a PVZ spectrum, which is expressed as a ratio of pressure and flow moduli and a phase angle, both as a function of frequency. The method has been applied to patients with PAH,17,18 but is complicated, and requires expensive high-fidelity technology that is not available in most catheterization laboratories. The clinical relevance of PVZ determinations is unknown. Right ventricular afterload can easily be evaluated by PAP and flow waveform analysis in the time domain. Increased pulmonary arterial elastance and wave reflection decrease the acceleration time, cause late or midsystolic deceleration of pulmonary arterial flow waves, and increase pulse pressure and late systolic peaking of pulmonary arterial pressure waves.10 Shortened acceleration times of pulmonary arterial flow have been associated with decreased survival in a small series of PAH patients.19 Increased pulse pressure has been reported to help in the differential diagnosis between PAH and chronic thrombo-embolic pulmonary hypertension, whether pressures are directly measured during a right heart catheterization,20 or re-calculated from tricuspid and pulmonary regurgitant waves and the simplified form of the Bernouilli equation.21 Refined indices of wave reflection such as the time to inflection point of the upstroke of RV pressure or the (peak pressure minus inflection point pressure) referred to mean PAP (called the ‘augmentation index’) may also be useful.22 However, discrepant results have been reported22,23 and therefore the diagnostic value of pulmonary pressure waveform analysis remains uncertain. Instead of trying to quantify the RV afterload by pulmonary pressure wave analysis, it might be more appropriate to quantify the RV function directly and to couple to the pulmonary circulation. Sunagawa et al.11 showed that this can be done graphically using a ventricular pressure–volume diagram. The diagram allows for the determination of maximal or end-systolic ventricular elastance (Ees), which is the best possible load-independent measurement of contractility, of arterial elastance, Ea, as a measurement of afterload as it is ‘seen’ by the ventricle, and of the calculation of an Ees/Ea ratio as a measurement of the coupling of ventricular to arterial function. Complex mathematical modelling shows that the optimal matching of systolic ventricular and arterial elastances occurs at an Ees/Ea ratio of 1.5. Isolated increase in Ea, or decrease in Ees, decreases the Ees/Ea ratio, indicating uncoupling of the ventricle from its arterial system. Everything else being the same, a decrease in Ees/Ea is accompanied by a decrease in stroke volume. On the other hand, an isolated increase in preload is associated with an increase in stroke volume with unaltered ventriculo-arterial coupling. However, the complex geometry of the RV makes functional evaluations with measurement of instantaneous volume changes technically difficult, and the determination of Ees may be unreliable because of the triangular Right ventricular function in pulmonary hypertension H7 shape of the RV pressure–volume loop resulting from the fact that RV ejection continues after end-systole. This problem can be overcome by measuring pressure–volume loops at several levels of preload,24 but bedside manipulations of venous return are too invasive to be ethically acceptable. In addition, when applied to intact animals, changes in venous return are associated with reflex sympathetic nervous system activation, which affects the ventricular function that is measured. These concerns have been addressed by a most recently reported single-beat method allowing for a direct quantification of the coupling of the RV to the pulmonary circulation.25 The approach had initially been proposed for the left ventricle by Sunagawa et al.26 In its principle, the method avoids absolute volume measurements and related technical complexities, to calculate Ees and Ea from instantaneous RV pressure and flow output measurements. As shown in Figure 1, a Pmax is estimated from a non-linear extrapolation of the early and late systolic isovolumic portions of the RV pressure curve. This estimated Pmax has been shown to be tightly correlated with Pmax directly measured during a non-ejecting beat.25 A straight line drawn from Pmax to the RV pressure vs. relative change in volume curve allows for the determination of Ees. A straight line drawn from the Ees point to the end-diastolic relative volume point allows for the determination of Ea. The Ees/Ea ratio determined by the single-beat method is 1.5, which is similar to values reported for left ventricular-aortic coupling, and compatible with an optimal ratio of mechanical work to oxygen consumption.11 The Ees/Ea ratio is decreased by propranolol and increased by dobutamine, and maintained in the presence of increased Ea because of hypoxic pulmonary vasoconstriction.25 In fact, Ees increases adaptedly to increased Ea in hypoxia, even in the presence of adrenergic blockade, which is compatible with the notion of homeometric adaptation of RV contractility.25 On the other hand, the approach allows for the demonstration that clinically relevant doses of dobutamine do not affect pulmonary arterial hydraulic load.25,27 The single beat approach has also already been used to show the superiority of dobutamine over norepinephrine to restore right ventriculo-arterial coupling in acute right heart failure produced by a brisk increase in PAP.27 Also, the optimal values for the Ees/Ea ratio were shown to be well maintained in piglets with PAH induced by 3 months systemic to pulmonary shunting, without or with endothelin receptor blocker therapy.28 Furthermore, the method showed that, in contrary to the current belief,29 prostacyclin iv has no intrinsic positive inotropic effects on the right ventricle.30 The single-beat method was also applied to an asymptomatic patient with congenitally corrected transposition of the great arteries.31 The coupling between the native RV and the systemic arterial system was shown to be altered, with an Ees/Ea ratio down to 1.16, whereas the native LV was perfectly coupled to the pulmonary arterial system with an Ees/Ea of 1.67 (Figure 2). This observation suggested that an RV coupled to a high-pressure arterial system from birth is nevertheless chronically uncoupled, probably because of inherent structural characteristics, accounting for eventual clinical heart failure and decreased life expectancy. Practically, all that is needed to determine single-beat Ees/Ea ratios is measurements of instantaneous pulmonary blood flow and RV pressure. This is feasible by echocardiography. Doppler pulmonary flow measurements synchronized to invasively measured PAPs have been reported to allow for accurate pulmonary arterial impedance calculations.18 Right ventricular pressure can be re-calculated from the envelope of tricuspid regurgitant jets and point-by-point application of the simplified form of the Bernouilli equation.32 However, the entirely non-invasive Doppler echocardiographic determination of Ees/Ea ratios in patients has not yet been validated. Most recently, Figure 1 Instantaneous measurements of right ventricular pressure and relative changes in volume in a dog, with calculation of a maximum ventricular pressure (Pmax) and graphical determinations of end-systolic elastance (Ees) and arterial elastance (Ea), leading to a ratio of elastances of 1.7. (Adapted from Brimioulle et al.25, with permission.) Figure 2 Right ventricular-aortic artery and left ventricular-pulmonary artery coupling in a patient with congenitally corrected transposition. The ratio of elastances is decreased for the native right ventricle (Ees/ Ea ¼ 1.2) and normal for the native left ventricle (Ees/Ea, 1.7). (Adapted from Wauthy et al.31, with permission.) H8 R. Naeije and S. Huez performance (calculated as the sum of isovolumetric contraction and relaxation times divided by stroke volume), right heart chamber dimension measurements, which are determined by both systolic and diastolic function changes at given levels of load, circulating biomarkers such as brain natriuretic peptide, which are released by myocardial stretch, and even heart rate variability which is affected by neurohumoral activation in (right) heart failure. However, there was a mention of pressure–volume or pressure–area loops, much closer to intrinsic RV function and its adaptation to loading conditions, and the report evoked the interest of tissue Doppler imaging. The importance of the RV ventricle in cardiovascular diseases was underscored, and there was a call for more translational cellular and molecular research with improved definition of parameters of function.34 Symptoms of pulmonary hypertension are predominantly caused by RV dysfunction. The evaluation of pulmonary hypertension by the steady flow haemodynamic approach and a calculation of PVR is essential to the accurate measurement of resistive vessel obstruction, but does not accurately explain the RV’s adaptation to an associated increase in afterload. This can be accomplished using newer non-invasive methods, methods needing urgent validation. Acknowledgements Figure 3 Right ventricular pressure–volume loops showing in a patient with pulmonary arterial hypertension and in a control, showing uncoupling of the right ventricle in the patient in spite of an increased contractility. The figure also shows MRI imaging of the right ventricle. (Adapted from Kuehne et al.33, with permission.) Kuehne et al.33 used magnetic resonance imaging together with RV pressure measurements to generate pressure– volume loops and to determine Ees and Ea values in patients with PAH. As compared with controls, RV Ees was increased from 5.2 + 0.9 to 9.2 + 1.2 mmHg/mL per 100 g (P , 0.05), but RV Ees/Ea was decreased from 1.9 + 0.4 to 1.1 + 0.3 (P , 0.05), indicating an increased RV contractility in response to increased afterload that was, however, insufficiently coupled to its hydraulic load, with inefficient mechanical work production (Figure 3). It will be interesting to correlate these findings to newly developed tissue Doppler indices of RV function. Conclusions A most recent report of a National Heart, Lung and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure identified a series of markers of RV dysfunction associated with clinical status and prognosis.34 The list included both load- and contractility-sensitive RV function measurements such as ejection fraction, tricuspid annular velocity or excursion, dP/dt, tricuspid regurgitation, and the index of The work was supported by Grant no. 3.4551.05 from the Fonds de la Recherche Scientifique Médicale and by the Foundation for Cardiac Surgery. S.H. is a fellow of the Fonds National de la Recherche Scientifique, Belgium. Conflict of interest: none declared. References 1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655–1665. 2. Dantzker DR, Bower JS. Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease. J Clin Invest 1979;64:1050–1055. 3. Melot C, Naeije R, Mols P, Vandenbossche JL, Denolin H. Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension. Chest 1983;83:203–207. 4. Dantzker DR, D’Alonzo GE, Bower JS, Popat K, Crevey BJ. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. Am Rev Respir Dis 1984;130:412–416. 5. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation 2001; 104:429–435. 6. Deboeck G, Niset G, Lamotte M, Vachiéry J-L, Naeije R. Cardiopulmonary exercise testing in pulmonary arterial hypertension and in congestive heart failure. Eur Respir J 2004;23:747–751. 7. Fleg JL, Pina IL, Balady GJ. Assessment of functional capacity in clinical and research applications: an advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, American Heart Association. Circulation 2000;102:1591–1597. 8. Cooper KH. A means of assessing maximal oxygen intake. Correlation between field and treadmill testing. JAMA 1968;203:135–138. 9. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of 6 min walk test in patients with pulmonary hypertension. Right ventricular function in pulmonary hypertension 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–492. Naeije R. Pulmonary vascular function. In: Peacock AJ, Rubin LJ, ed. Pulmonary Circulation. London: Arnold; 2004. p3–11. Sagawa K, Maughan L, Suga H, Sunagawa K. Cardiac contraction and the pressure–volume relationship. New York: Oxford University Press; 1988. D’Alonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K, Fishman A, Goldring R, Groves B, Kernis J, Lavy P, Pietra G, Reid L, Reeves J, Rich S, Vreim C, Williams G, Wu M. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Int Med 1991;115:343–349. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch D, Groves B, Tapson V, Bourge R, Brundage BH, Koerner SK, Langleben D, Keller C, Murali S, Uretsky B, Clayton L, Jöbsis M, Blackburn S, Sortino D, Crow JW, for the primary pulmonary hypertension study group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780–788. McLaughlin V, Shillington A, Rich S. Survival in primary pulmonary hypertension. The impact of epoprostenol therapy. Circulation 2002;106:1477–1482. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, Hervé P. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002;165:338–340. Laskey W, Ferrari V, Palevsky H, Kussmaul W. Pulmonary artery hemodynamics in primary pulmonary hypertension. J Am Coll Cardiol 1993; 21:406–412. Huez S, Brimioulle S, Naeije R, Vachiery JL. Feasibility of routine pulmonary arterial impedance measurements in pulmonary hypertension. Chest 2004;125:2121–2128. Eysmann SB, Palevsky HI, Reichek N, Hackney K, Douglas P. Two-dimensional and Doppler echocardiographic and cardiac catheterization correlates of survival in pulmonary hypertension. Circulation 1989;80:353–360. Nakayama Y, Nakanishi N, Sugimachi M, Takaki H, Kyotani S, Satoh T, Okano Y, Kunieda T, Sunagawa K. Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 1997;29:1311–1316. Nakayama Y, Sugimachi M, Nakanishi, Takaki H, Okano Y, Satoh T, Miyatake K, Sunagawa K. Noninvasive differential diagnosis between chronic pulmonary thromboembolism and primary pulmonary hypertension by means of Doppler ultrasound measurement. J Am Coll Cardiol 1998;31:1367–1371. Nakayama Y, Nakanishi N, Hayashi T, Nagaya N, Sakamaki F, Satoh N, Ohya H, Kyotani S. Pulmonary artery reflection for differentially H9 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. diagnosing primary pulmonary hypertension and chronic pulmonary thromboembolism. J Am Coll Cardiol 2001;38:214–218. Castelain V, Herve P, Lecarpentier Y, Duroux P, Simonneau G, Chemla V. Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 2001;37:1085–1092. Maughan WL, Shoukas AA, Sagawa K, Weisfeldt ML. Instantaneous pressure–volume relationship of the canine right ventricle. Circ Res 1979;44:309–315. Brimioulle S, Wauthy P, Ewalenko P, Rondelet B, Vermeulen F, Kerbaul F, Naeije R. Single-beat estimation of right ventricular end-systolic pressure–volume relationship. Am J Physiol Heart Circ Physiol 2003;284:H1625–H1630. Sunagawa K, Yamada A, Senda Y, Kikuchi Y, Nakamura M, Shibahara T. Estimation of the hydromotive source pressure from ejecting beats of the left ventricle. IEEE Trans Biomed Eng 1980;57:299–305. Kerbaul F, Rondelet B, Motte S, Fesler P, Hubloue I, Ewalenko P, Naeije R, Brimioulle S. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med 2004;32:1035–1040. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, McEntee K, Wauthy P, Salmon I, Ketelslegers JM, Naeije R. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003;107:1329–1335. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184–1187. Wauthy P, Abdel Kafi S, Mooi WJ, Naeije R, Brimioulle S. Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension. J Thorac Cardiovasc Surg 2003;126:1434–1441. Wauthy P, Naeije R, Brimioulle S. Left and right ventriculo-arterial coupling in a patient with congenitally corrected transposition. Cardiol Young 2005;15:647–649. Ensing G, Seward J, Darragh R, Caldwell R. Feasibility of generating hemodynamic pressure curves from noninvasive Doppler echocardiographic signals. J Am Coll Cardiol 1994;23:434–442. Kuehne T, Yilmaz S, Steendijk P, Moore P, Groenink M, Saaed M, Weber O, Higgins CB, Ewert P, Fleck E, Nagel E, Schulze-Neick I, Lange P. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: in vivo validation and clinical application in patients with pulmonary hypertension. Circulation 2004;110: 2010–2016. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB, National Heart Lung Blood Institute Working Group on Cellular Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure. Report of a National Heart, Lung and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Circulation 2006;114:1883–1891.